Broadfin Capital, LLC is 10% Owner at Recro Pharma, Inc. (REPH). They have made 17 open-market trades across 7 companies since 2015, most recently 2022-03-22.
CIK 0001511901
3 open-market purchases totalling $8.3M since 2015, against 14 sales. Too few scored purchases to measure a record yet.
| 7d | 30d | 90d | |
|---|---|---|---|
| Accuracy | 50% | 79% | 71% |
| Avg Move | -0.5% | -2.8% | -11.7% |
| Scored | 14 | 14 | 14 |
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| BDSI | BUY | 2021-11-12 | 2021-11-15 | $3.20 | $320K | -9.3% | -17.4% | +73.2% |
| BDSI | SELL | 2019-12-18 | 2019-12-20 | $6.40 | $12.8M | -10.0% | -11.8% | -48.0% |
| BDSI | SELL | 2019-05-10 | 2019-05-14 | $5.00 | $9.0M | -9.5% | -10.7% | -11.8% |
| REPH | SELL | 2018-05-24 | 2018-05-24 | $5.81 | $1.1M | -4.5% | -8.1% | +14.3% |
| REPH | SELL | 2018-03-13 | 2018-03-15 | $10.07 | $2.0M | +3.1% | +9.1% | -49.2% |
| PETX | SELL | 2017-12-01 | 2017-12-01 | $5.40 | $2.3M | +4.0% | -4.0% | -29.7% |
| REPH | SELL | 2017-11-30 | 2017-11-30 | $9.55 | $1.4M | -1.1% | -6.6% | -6.9% |
| PETX | SELL | 2017-11-29 | 2017-12-01 | $5.45 | $2.6M | +4.0% | -4.0% | -29.7% |
| REPH | SELL | 2017-11-28 | 2017-11-30 | $9.58 | $2.1M | -1.1% | -6.6% | -6.9% |
| REPH | SELL | 2017-11-28 | 2017-11-30 | $9.71 | $237K | -1.1% | -6.6% | -6.9% |
| CORI | SELL | 2017-11-17 | 2017-11-17 | $11.01 | $719K | +2.9% | -3.8% | +9.9% |
| MRTX | SELL | 2017-11-16 | 2017-11-20 | $18.05 | $1.1M | -9.9% | -9.4% | +49.5% |
| CORI | SELL | 2017-11-16 | 2017-11-17 | $11.00 | $825K | +2.9% | -3.8% | +9.9% |
| PGNX | SELL | 2017-02-13 | 2017-02-15 | $9.67 | $7.8M | +9.3% | +8.2% | -31.7% |
| PGNX | SELL | 2017-02-07 | 2017-02-09 | $9.71 | $3.4M | +3.7% | +18.5% | -26.0% |
| AEGR | BUY | 2016-09-09 | 2016-09-12 | $1.66 | $459K | +51.4% | +33.1% | N/A |
| REPH | BUY | 2015-07-07 | 2015-07-09 | $11.60 | $7.5M | -10.2% | -1.5% | -1.5% |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.
| Total | $304.4M |
Shares reported on the most recent Form 4, priced at the 2022-01-31 close.